MK-677 (ibutamoren) is an orally active, non-peptide ghrelin-mimetic growth hormone secretagogue, and every figure attached to its use comes from research protocols and self-reported anecdotal practice, not an approved dosing label. The honest bottom line is that the compound is not FDA-approved for human therapeutic use, so what follows documents study-protocol amounts and community practice rather than a therapeutic regimen.
Every MK-677 dosing figure derives from research protocols and self-reported anecdotal practice rather than an approved label, because ibutamoren is not FDA-approved for human therapeutic use and is sold as a research-use compound.
Human clinical investigations most often centered on a single oral 25 milligram daily dose, a figure that recurs across studies of body composition, bone turnover, and growth hormone response, while dose-finding work examined lower amounts down to 10 milligrams. The published record does not support a simple assumption that doubling the dose doubles the benefit, since growth hormone secretagogue response trends toward a ceiling and higher amounts mainly amplify side effects.
| Criteria | Clinical studies | Anecdotal protocols |
|---|---|---|
| Most-cited daily dose | 25 mg once daily | 10-25 mg once daily |
| Lower amount examined | 10 mg (dose-finding) | 10 mg (starting point) |
| Dosing duration studied | days up to ~1 year | weeks to many months |
| IGF-1 response reported | measurable at 10 mg | reported at 10 mg |
Controlled trials most often used a single 25 milligram daily dose while doses as low as 10 milligrams were reported to measurably raise insulin-like growth factor 1, and growth-hormone-secretagogue response trends toward a ceiling so higher amounts mainly amplify side effects.
Reported practice describes no single mandated administration time, and the split runs mainly between evening or pre-sleep dosing and morning dosing, each chosen for a different practical reason. Because a single dose sustains growth hormone elevation across much of the day, the record frames timing as a tolerability decision rather than a coverage requirement.
Reported practice describes no single mandated administration time, since a once-daily schedule covers the dosing interval regardless of hour and total daily growth hormone and insulin-like growth factor 1 response appears relatively insensitive to the exact clock time of the dose.
The most commonly cited justification rests on the body's own physiology, since the largest natural pulse of growth hormone occurs during early deep sleep and users reason that a bedtime ghrelin-mimetic stimulus layers onto that surge. The alignment argument is plausible on mechanism, but the practical sleep tradeoff is individual, so bedtime dosing is documented as a common preference rather than an established optimal practice.
The evening-dosing preference rests on the largest natural growth hormone pulse occurring during early deep sleep, an alignment rationale that remains a common anecdotal preference rather than an established optimal practice for an unapproved compound.
As an orally active non-peptide small molecule, MK-677 does not depend on a fasted state for absorption the way an injectable peptide secretagogue would, so food presence is generally treated as a non-critical variable. Where food enters the decision is through the compound's pronounced appetite stimulation, which is a comfort and lifestyle consideration rather than a pharmacological requirement.
Because MK-677 is an orally active non-peptide small molecule, no strong evidence indicates a fasted state improves its bioavailability or growth hormone response, so food presence is documented as a comfort and lifestyle variable rather than a pharmacological requirement.
The pharmacokinetics are central to why the compound is almost always taken once per day, and the driver is sustained signaling rather than the raw half-life number. A single oral dose is reported to produce a prolonged growth hormone elevation and a sustained IGF-1 increase that carries the effect through to the next day's dose.
A single oral dose of MK-677 is reported to sustain elevated growth hormone and insulin-like growth factor 1 across roughly a 24-hour interval, and this continuous elevation, rather than the 4-to-6-hour half-life number, is what the record credits for once-daily administration.
Reported use patterns span a wide spectrum, from short runs of a few weeks to extended continuous daily dosing measured in many months. Human clinical dosing periods extended to about a year in older adults, which establishes that prolonged continuous use has been formally examined rather than only assumed.
The longest controlled MK-677 dosing periods extended to about a year in older adults, and because daily dosing maintains a steady elevation of insulin-like growth factor 1 rather than a pulse needing a recovery window, continuous use is the frequently reported pattern rather than traditional on-off cycling.
Titration practice for MK-677 is anecdotal rather than protocol-defined, and the common pattern begins low to gauge individual tolerance before any move toward the more frequently cited 25 milligram level. The escalation, when it happens, is documented as unhurried, since the slower-building IGF-1 effects and early side effects take time to surface.
Anecdotal titration practice begins near 10 milligrams daily held for one to two weeks before any move toward 25 milligrams, and splitting a daily dose offers little pharmacological advantage because a single dose already provides sustained coverage through the long IGF-1 response.
MK-677 is administered orally and is encountered in three main physical forms, each carrying different implications for how a dose is measured and how reliable that measurement is. The underlying complication across all forms is that a research-grade compound sits outside pharmaceutical quality control, so labeled content and actual content can diverge.
MK-677 is encountered orally as pre-dosed capsules, liquid or suspension, or raw powder, and because it is an unapproved research-grade compound outside pharmaceutical quality control, independent assay of identity and purity is the only way to confirm what a given product actually contains.
Educational use only. This article describes what the published scientific and clinical literature reports about MK-677. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
